Stockreport

Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)

Denali Therapeutics Inc.  (DNLI) 
Last denali therapeutics inc. earnings: 8/6 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.denalitherapeutics.com
PDF Denali plans to continue clinical development of DNL593, which is designed to deliver progranulin to the brain using TransportVehicleâ„¢ technologyResults from ongoing Pha [Read more]